Video

Dr. Scagliotti Discusses Elderly Lung Cancer Therapy

Dr. Giorgio Scagliotti from University of Turin Discusses Elderly Lung Cancer Therapy

Giorgio V. Scagliotti, MD, PhD, head of the Thoracic Oncology Unit, Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Orbassano, Italy, discusses the challenges facing lung cancer treatment in elderly populations.

Scagliotti explains that elderly patients now represent approximately 30% of new non-small cell lung cancer (NSCLC) patients. Despite this fact there hasn't been any major recent advances in the treatment of elderly patients with NSCLC.

The current standard treatment for NSCLC is chemotherapy that is either a targeted therapy or a classic cytotoxic agent. Administering combination therapies becomes difficult for elderly patients because only a minority is fit enough for this type of treatment.

The degree of comorbid conditions is increased in elderly patients due to their physiological state. These conditions are exceptionally common when giving cisplatin, which is the backbone of many combinations therapies.

Related Videos
Lajos Pusztai, MD, DPhil
Hope S. Rugo, MD
Marc Machaalani, MD
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Coral Olazagasti, MD
Barbara Jane O’Brien, MD, associate professor, Neuro-Oncology, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center